News >

Promising PARP Inhibitor Strategies Emerging in Platinum-Sensitive Ovarian Cancer

Ellie Leick
Published: Wednesday, Jul 24, 2019

Richard T. Penson, MD, MRCP, associate professor, Harvard Medical School, and clinical director, Medical Gynecologic Oncology, Massachusetts General Hospital

Richard T. Penson, MD, MRCP

Incorporating switch maintenance therapy with PARP inhibitors earlier in the treatment of patients with platinum-sensitive ovarian cancer may control the disease for longer periods of time. This may be a more important goal than response rate or overall survival (OS) in patients who are likely to recur, according to Richard T. Penson, MD, MRCP.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Community Practice Connections™: Advances in Ovarian Cancer: Evolving Applications for PARP Inhibitors, Immunotherapy & Beyond!Aug 30, 20201.5
Publication Bottom Border
Border Publication
x